Vaxart Shares Plunge On Not So Great Data From COVID-19 Oral Vaccine Study
Portfolio Pulse from Vandana Singh
Vaxart Inc's shares plummeted over 56% after Phase 1 trial results showed no neutralizing antibodies detected in volunteers after a single dose of its oral COVID-19 vaccine. The vaccine did generate T-cells in 75% of volunteers, and no severe adverse events were reported.
February 03, 2021 | 3:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vaxart's stock dropped significantly after disappointing Phase 1 trial results for its oral COVID-19 vaccine, which showed no neutralizing antibodies after a single dose.
The lack of neutralizing antibodies in the trial results is a significant setback for Vaxart's oral COVID-19 vaccine, leading to a sharp decline in investor confidence and a 56% drop in stock price. The generation of T-cells and absence of severe adverse events are positive, but the primary focus is on the lack of antibodies, which are crucial for vaccine efficacy.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100